GenMont BiotechTPE:3164 +0.30%82 Days Payable is 16.98 as of Dec. 2025, which is 47% below its 10-year median of 32.30. GuruFocus rates TPE:3164 with a GF Score™ of 82/100 and a GF Value™ of NT$26.24 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 699 Biotechnology companies, GenMont Biotech ranks worse than 90.7% on this metric.
The historical rank and industry rank for GenMont Biotech's Days Payable or its related term are showing as below:
TPE:3164'
s Days Payable Range Over the Past 10 Years
Min: 17.55 Med: 32.3 Max: 73.85
Current: 17.65
During the past 13 years, GenMont Biotech's highest Days Payable was 73.85. The lowest was 17.55. And the median was 32.30.
TPE:3164's Days Payable is ranked worse than 90.7% of 699
companies
in the Biotechnology industry
Industry Median: 112.84
vs TPE:3164: 17.65
GenMont Biotech's Days Payable
increased
from Dec. 2024 (10.63) to Dec. 2025 (16.98).
It may suggest that GenMont Biotechdelayed paying its suppliers.
GenMont Biotech Days Payable Related Terms
GenMont Biotech Days Payable Historical Data
* Premium members only.
The historical data trend for GenMont Biotech's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:3164 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, GenMont Biotech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GenMont Biotech Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GenMont Biotech's Days Payable distribution charts can be found below:
* The bar in red indicates where GenMont Biotech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
GenMont Biotech's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GenMont Biotech (TPE:3164) has a Days Payable of 16.98 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on GenMont Biotech and its competitors. This is 47% below median its historical median of 32.30. Over the past decade, GenMont Biotech's Days Payable has ranged from 17.55 to 73.85. According to the industry distribution chart, GenMont Biotech ranks #634 out of 699 companies in the Biotechnology industry, placing it in the top 90.7%.
Is GenMont Biotech's Days Payable too high?
GenMont Biotech's current Days Payable of 16.98 is 47% below median its 10-year median of 32.30. Over the past 10 years, this metric has ranged from a low of 17.55 to a high of 73.85. The Biotechnology industry median Days Payable is 112.84. GenMont Biotech's value of 16.98 is 85% below this industry median. Based on the distribution chart, GenMont Biotech ranks #634 out of 699 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, GenMont Biotech has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GenMont Biotech's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GenMont Biotech ranks #634 out of 699 companies for Days Payable. This places GenMont Biotech in the lower half of its industry. The industry median Days Payable is 112.84. GenMont Biotech's value of 16.98 is 85% below this benchmark. Historically, GenMont Biotech's own Days Payable has ranged from 17.55 to 73.85 over the past decade. While the company's 10-year median is 32.30 vs. the industry median of 112.84, GenMont Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GenMont Biotech's current Days Payable of 16.98 is 85% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on GenMont Biotech and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GenMont Biotech's current Days Payable is 16.98, which is 47% below median its own 10-year median of 32.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GenMont Biotech stock overvalued right now?
Based on GuruFocus' analysis, GenMont Biotech (TPE:3164) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$26.24, compared to a current price of NT$16.55 — trading 36.9% below its estimated fair value. The current Days Payable is 16.98, which is 47% below median its 10-year median of 32.30 and 85% below the Biotechnology industry median of 112.84. GenMont Biotech's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For GenMont Biotech (TPE:3164), the current Days Payable is 16.98 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GenMont Biotech (TPE:3164) Overvalued in 2026?
Based on GuruFocus' analysis, GenMont Biotech stock appears to be undervalued.
The current stock price of NT$16.55 is trading 36.9% below its estimated GF Value™ of NT$26.24.
GuruFocus considers GenMont Biotech to be Significantly Undervalued.
Key valuation signals for TPE:3164:
Days Payable: 16.98 (47% below median its 10-year median of 32.30)
GF Value™: NT$26.24 vs. price of NT$16.55 (36.9% below fair value)
Industry Position: 85% below the Biotechnology median (#634 of 699)
No single metric tells the full story. See the TPE:3164 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenMont Biotech Inc is engaged in the research, development, manufacturing, and selling of a variety of probiotic supplements. The Group mainly engages in the manufacturing and selling of functional foods, its single operating segment.
82GF Score
Get the complete analysis for TPE:3164
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:3164 has been successfully added to your 
